We Don’t Wait for Change. We Build It.
How Seek Labs’ BioSeeker Is Redefining the Fight Against Disease
Jared Bauer, CEO of Seek LAbs | June 10, 2025
I’ve spent most of my life watching disease move faster than the systems built to stop it–faster than diagnostics, faster than therapeutics, faster than public policy. And behind that speed is something deeply human: fear, grief, absence. The kind that leaves a permanent mark. My son, Oliver Edmund Wayne Bauer, was born on Father’s Day in 2008. He passed away on Valentine’s Day the following year from complications that ultimately ended with influenza, confirmed on his death certificate.
He died in my arms at Primary Children’s Medical Center.
We miss him every day.
So when I say this fight is personal, I mean it in the most literal way possible. Seek Labs was built with one belief at its core: people should not have to wait for science to catch up with disease. Especially not in the moments that matter most.
Today, we’re launching BioSeeker, a system designed to change the speed, precision, and structure of how we fight disease. This isn’t just a product. It’s a response. A reframing of what health systems can be.
Because the next Oliver–and there will be others–deserves a better chance.
What We Built and Why
We’ve spent the past eight years quietly building these systems: not just one, but many. BioSeeker, PTAP, and SeekIt each serve a distinct role, and underneath them are foundational technologies like room-temperature isothermal amplification and nucleic acid extraction, purpose-built to enable precision in the moments that matter most.
BioSeeker is our AI-powered engine that identifies pathogen-specific vulnerabilities–fast, precisely, and at scale. It’s not a therapeutic itself, but the intelligence layer behind our systems. It informs PTAP, enabling us to design highly specific CRISPR-based treatments. It also powers SeekIt, guiding where and how to detect with precision. This is targeted, actionable insight not passive data.
In parallel, we built:
- PTAP: our Programmable Target Ablation Platform that rapidly generates custom CRISPR candidates.
- SeekIt: a rapid, portable diagnostic device that delivers results in minutes, not hours, and works in field, clinical, or crisis settings.
Together, they form a system, not a pipeline, capable of acting on disease in real time.
The ASFV Case Study: Proof the System Works
African Swine Fever Virus (ASFV) devastates farms, with near 100% mortality in affected pigs and billions in agricultural losses every year. Families lose income. Economies lose stability. No treatments exist–until now.
Using this new therapeutic approach, we generated a CRISPR therapeutic candidate. In early preclinical models, that candidate delivered survival outcomes that exceed any published preclinical standards for ASFV.
BioSeeker’s preclinical results show a 57% survival rate for ASFV, far surpassing untreated outcomes.
From Reaction to Readiness
Biotech has historically been reactive. We wait for outbreaks, then scramble to respond. But that’s not a sustainable model; not for pandemics, not for zoonotic spillover (when diseases jump from animals to humans), and certainly not for families watching hospital monitors in the middle of the night.
BioSeeker changes the model.
It lets us go from sequence to therapeutic–repeatedly–for dozens of viral threats in days; not weeks, not months, not years. Fast. Precise. Planned. And built to act again and again, creating a modular response engine that never starts from scratch.
It’s not a pipeline. It’s infrastructure.
The Disease Atlas: Mapping the Path Ahead
We’re now scaling BioSeeker to build a Disease Atlas, a real-time genomic map of vulnerabilities across 100+ high-priority infectious diseases. Not to study them. To act on them.
Picture the Disease Atlas as a global radar for pathogens, spotting their weaknesses and arming us with solutions before they strike. To be ready before the next wave. The next mutation. The next loss.
The Disease Atlas is our commitment to a future where health systems anticipate, rather than scramble. And where programmable therapeutics can be built, tested, and delivered at the speed of outbreaks–not in their aftermath.
Why Now, and Why Seek Labs
I didn’t start Seek Labs to build a better diagnostic or a faster therapeutic. I started it because I never wanted to see another family experience what mine did.
That conviction led us here; to a system that links discovery with action, and vision with execution. A system built not around press cycles or market fads, but around the simple urgency of people who can’t afford to wait.
The People Who Built It
This work didn’t happen overnight and it didn’t happen alone. The system we’ve built stands on the shoulders of our Seekers: scientists, engineers, designers, and dreamers who’ve poured years into getting this right. They believed in a future where response beats reaction and they made it real.
Every insight. Every breakthrough. Every step forward has their fingerprints on it.
An Open Invitation
Today is a milestone. But it’s not a victory lap. We’re just getting started.
Over the coming months, we’ll release new targets. New data. New collaborations. And we’ll continue building this system for a world that needs to move faster; not in panic, but in purpose. If you’re an investor, researcher, or health leader who believes we can do better, we invite you to build with us. For the families. For the communities. For the people like Oliver–and the many others–who deserved more time.
The future of health isn’t something we wait for. It’s something we build. Together.